Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with ...

The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...

German drugmaker Bayer (BAYN: DE) has signed a global licensing agreement with China-based Puhe BioPharma, gaining exclusive ...

Bayer (BAYZF) stock in focus as the company inks a licensing deal with Puhe BioPharma to develop a cancer candidate targeting ...

German pharmaceutical company Bayer (BAYRY) said on Wednesday it has entered into a global license agreement with China’s ...

Even still, the pharma deals announced out of the event brought a clear message for the biotech industry. Technology ...

Bayer was ordered to pay more than $2 billion by a jury in a Georgia state court in the latest legal case surrounding alleged ...

The US Food and Drug Administration (FDA) accepted and granted Priority Review designation for Bayer’s (BAYN: DE) supplemental new drug application (sNDA) for a new indication for Kerendia (finerenone ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.